摘要
肝素结合表皮生长因子属表皮生长因子超家族成员之一,可促进多种细胞分裂和增殖,参与多个病理生理过程。近年研究发现肝素结合表皮生长因子可参与肿瘤发生发展的各个环节,在肿瘤化疗耐药中也发挥一定作用,使其成为恶性肿瘤生物学治疗的靶向因子。其与白喉毒素结合的特性为临床提供了一种新的治疗癌症的途径。继续对HB-EGF进行深入的研究,并将已获得的知识与临床治疗结合,将有望产生新的治疗恶性肿瘤的途径及新型的抗肿瘤药物。
Heparin-binding epidermal growthfactor （HB-EGF）, which belongs to the epidermal growthfactor （EGF） family, has been implicated as a contributer to a variety of physiological and pathological processes. Moreover, HB-EGF has been shown to stimulate the growth and proliferation of variety of cells .In recent years, HB-EGF has also been found to be implicated in each of the hallmarks characteristic of neoplastic disease and in the resistance to chemotherapy of tumor making it a targeted factor for biological therapy of cancer.Its unique identity as a receptor for diphtheria toxin may provide novel avenues for cancer therapeutics.The future challenge will be to lueubrate HB-EGF and to translate our knowledge of this inimitable molecule into treatments,then we can expected new ways and new drugs for cancer.
出处
《现代生物医学进展》
CAS
2012年第23期4566-4568,4559,共4页
Progress in Modern Biomedicine
